Immuron Ltd has released a press release.
Trading Halt
Filed with ASX ·
On 6ix: 6ix.com/news/trading-halt-903
6ix hasn’t read this filing yet.
Earlier from Immuron
- Immuron Plans Phase 2 Trial for IMM-529 following FDA review
- Appendix 4E and Preliminary Final Report
- Immuron Travelan record sales globally, Australia and USA
- IMM-529 pre-IND FDA filing
- Immuron Travelan sales continued strong growth
Later from Immuron
- NMRC Reports Results for Campylobacter Clinical Study
- Immuron Announces Travelan Clinical Trial Update
- Immuron Travelan continued strong sales growth
- IMC and Calmino to treat Irritable Bowel Syndrome (IBS)
- Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron